 |
| Engineered antibodies (green/red) bound to carbon-nanotube transistors that detect osteopontin, a prostate cancer biomarker. (Courtesy: University of Pennsylvania) |
What if detecting cancer could be as quick and straightforward as a routine blood test? Researchers at the University of Pennsylvania have taken a meaningful step in that direction, showing that carbon-nanotube transistors can sniff out disease biomarkers at incredibly tiny concentrations — far beyond what conventional lab methods can achieve.
The team focused on a protein called osteopontin (OPN), which is a known marker for prostate cancer and several other malignancies. By chemically bonding engineered antibody fragments directly onto carbon nanotube field-effect transistors (NT-FETs), they created biosensors that respond electrically whenever OPN binds to the antibody. In other words, the cancer biomarker essentially announces its own presence by changing how electricity flows through the nanotube device.
A Thousand Times More Sensitive
The numbers here are striking. The nanotube sensors managed to detect OPN at concentrations as low as 1 picogram per milliliter — roughly 1,000 times more sensitive than the standard ELISA immunoassay tests currently used in clinical settings. And while ELISA tests can take days to return results, these nanotube sensors deliver readings in just minutes.
Mitchell Lerner, one of the researchers on the project, put it plainly: their sensors are simpler, faster, and vastly more sensitive than existing clinical tools. That kind of leap in performance matters enormously when early detection is so critical to cancer outcomes.
How the Technology Works
The antibody fragments used are genetically engineered single-chain variable fragments (scFv) — compact, highly specific molecules that latch onto OPN with great affinity. The team attached these to the nanotube transistors using a process called diazonium salt functionalization, which creates a stable covalent bond without destroying the antibody's binding ability.
When OPN molecules in a sample bind to these antibodies, they alter the electrical properties of the nanotube — specifically, they change the current flowing through the transistor. That change becomes the detection signal. The sensors also showed strong selectivity, meaning they responded to OPN without being thrown off by other proteins in the background.
Why It Matters Beyond Prostate Cancer
Osteopontin is elevated in several types of cancer, not just prostate cancer, which means this detection approach could potentially be adapted to screen for a range of malignancies. The team also noted that the functionalization method they developed should work for any antibody with an accessible amine group — making this a platform technology, not just a one-off solution.
We're still some distance from seeing nanotube transistors in clinical labs, but the proof-of-concept is compelling. Faster, cheaper, and far more sensitive cancer detection tools could one day make early diagnosis accessible to far more patients — and that's an outcome worth working toward.
Source: Physics World
1 comments:
Thanks for sharing the information about this techniques. The Detecting of minute quantities of disease biomarkers is really an improvement
Post a Comment